Funding for this research was provided by:
U.S. Army Materiel Command (W81XWH-10-1-0046)
the Dr. Carolyn S. Glaubensklee Endowed Cancer Center Directorship
the California University of Science and Medicine
Received: 24 July 2020
Accepted: 12 March 2021
First Online: 27 May 2021
: No human subjects nor human materials, human data, or human tissues were used in the study. Initial animal studies were approved by The Ohio State University’s Animal Care and Use Committee (IACUC), protocol 2007A0218, and by The Ohio State University’s Institutional Biosafety Committee, protocol 2007R0057, and additional animal studies were approved by the University of Nevada’s School of Medicine and the Nevada Cancer Institute’s IACUC, protocols 00439 and 00440, when the corresponding author of this study was affiliated with these previous institutions. Final animal studies were conducted under an Interinstitutional Agreement between the California University of Science and Medicine and Anticancer, Inc. using the latter’s IACUC protocol D16-00503 and OLAW A3873-01.
: Not applicable.
: The authors declare that they, at the present time, have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. None of the sources of support listed influenced the collection, analysis, and interpretation of data, the generation of the hypothesis, the writing of the manuscript, or the decision to submit the manuscript for publication.